Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Table 6 The comparison of PFS and OS in the subgroup of CLL patients

Group	Numbers	PFS (range)	P value	OS (range)	P value
MRD			0.002		0.001
≥ 1 %	117	36 (26.8 ~ 45.1)		72 (63.4 ~ 98.6)
< 1 %	31	Not reached		Not reached
LDH			0.001		<0.001
≥ 220U/L	38	29 (19.2 ~ 38.8)		37 (28.5 ~ 45.5)
< 220U/L	83	52 (35.0 ~ 68.9)		162 (70.7 ~ 253.3)
CR			<0.001		<0.001
Yes	38	110 (27.2 ~ 192.8)		63 (41 ~ 85)
No	111	36.0 (29.0 ~ 43.0)		25 (11 ~ 39)
CR + PR			<0.001		<0.001
Yes	88	63.0 (36.0 ~ 90.0)		120.0 (93.2 ~ 146.8)
No	61	25.0 (18.1 ~ 31.9)		43.0 (28.8 ~ 57.2)
β2-MG (mg/L)			0.003		0.001
≥ 3.5	51	32 (22.7 ~ 41.3)		57.0 (38.1 ~ 75.9)
< 3.5	42	Not reached		Not reached
Cytogenetic abnormalities			0.005		0.013
High -risk	37	28 (14.5 ~ 41.5)		60 (49.2 ~ 70.8)
Non high-risk	61	84 (17.8 ~ 150.2)		Not reached

ISSN: 1471-2407